 |
|
Prostate cancer vaccines more effective with hormone therapy
July 10, 2008PHILADELPHIA - Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
Philip M. Arlen, M.D., director of the Clinical Research Group for the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, at the National Cancer Institute, said the findings have important implications for guiding treatment decisions for prostate cancer patients.
"Vaccines, if and when they are approved, can be safely and effectively combined with other therapies, including hormones," said Arlen. "There appears to be an advantage in overall survival."
Arlen and colleagues enrolled 42 patients who had castration-resistant prostate cancer. These patients were randomly assigned to receive either a poxvirus-based prostate-specific antigen vaccine or hormone therapy with nilutamide. At progression, patients received the other therapy and continued to receive their original therapy.
For all the patients enrolled in the study, the three-year survival probability was 71 percent and the median overall survival was 4.4 years. Patients randomized to the vaccine had a three-year survival probability of 81 percent and an overall survival of 5.1 years, while patients taking nilutamide had a three-year survival probability of 62 percent and an overall survival of 3.4 years.
Of the 42 patients in the study, 12 patients who were originally assigned to vaccine switched to nilutamide plus vaccine and eight patients who were originally assigned to nilutamide switched to vaccine plus hormone, due to rising levels of prostate-specific antigen with no evidence of metastasis. For patients who received vaccine and then nilutamide, the three-year survival probability was 100 percent with a median overall survival of 6.2 years. For patients who switched to the vaccine after hormone, the three-year survival probability was 75 percent with a median overall survival of 3.7 years.
Arlen said the hormone therapy in combination with the vaccine works in two ways.
"By using hormone therapy in prostate cancer you can help enhance your T-cell response to where the cancer is in the prostate gland, and you are also more likely to achieve a better immune response," said Arlen.
Building on the results of this phase II study, researchers have developed another generation of this vaccine by adding molecules which boost T-cell responses.
Based on the current pace of vaccine research overall, Arlen predicts that men with prostate cancer could potentially see an effective, new treatment vaccine within the next several years.
"Phase II trials such as this one are adding to our knowledge, and other phase III trials are getting ready to publish their data," said Arlen. "If the phase II data hold up in phase III trials, we could see a new treatment vaccine within a few years."
American Association for Cancer Research
Arlen and colleagues enrolled 42 patients who had castration-resistant prostate cancer. These patients were randomly assigned to receive either a poxvirus-based prostate-specific antigen vaccine or hormone therapy with nilutamide. At progression, patients received the other therapy and continued to receive their original therapy.
For all the patients enrolled in the study, the three-year survival probability was 71 percent and the median overall survival was 4.4 years. Patients randomized to the vaccine had a three-year survival probability of 81 percent and an overall survival of 5.1 years, while patients taking nilutamide had a three-year survival probability of 62 percent and an overall survival of 3.4 years.
Of the 42 patients in the study, 12 patients who were originally assigned to vaccine switched to nilutamide plus vaccine and eight patients who were originally assigned to nilutamide switched to vaccine plus hormone, due to rising levels of prostate-specific antigen with no evidence of metastasis. For patients who received vaccine and then nilutamide, the three-year survival probability was 100 percent with a median overall survival of 6.2 years. For patients who switched to the vaccine after hormone, the three-year survival probability was 75 percent with a median overall survival of 3.7 years.
Arlen said the hormone therapy in combination with the vaccine works in two ways.
"By using hormone therapy in prostate cancer you can help enhance your T-cell response to where the cancer is in the prostate gland, and you are also more likely to achieve a better immune response," said Arlen.
Building on the results of this phase II study, researchers have developed another generation of this vaccine by adding molecules which boost T-cell responses.
Based on the current pace of vaccine research overall, Arlen predicts that men with prostate cancer could potentially see an effective, new treatment vaccine within the next several years.
"Phase II trials such as this one are adding to our knowledge, and other phase III trials are getting ready to publish their data," said Arlen. "If the phase II data hold up in phase III trials, we could see a new treatment vaccine within a few years."
American Association for Cancer Research
Hormone Therapy News and Current Hormone Therapy Events RSSHormone replacement therapy improves sleep, sexuality and joint pain in older women
One of the world's longest and largest trials of hormone replacement therapy (HRT) has found that post-menopausal women on HRT gain significant improvements in quality of life.
Why a common treatment for prostate cancer ultimately fails
Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.
Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy
Low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in a group of patients with HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection.
Treatment delays result in poor outcomes for men with breast cancer
Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show.
Elevated biomarkers predict risk for prostate cancer recurrence
A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.
Complex Changes in the Brain's Vascular System Occur after Menopause
Many women experience menopausal changes in their body including hot flashes, moodiness and fatigue, but the changes they don't notice can be more dangerous.
Estrogen therapy helps or hurts the brain depending on reproductive status
Estrogen therapy may limit stroke damage if started close to, but not long after reproductive cycles are over, according to a new animal study. The results were presented Sunday, June 15, at The Endocrine Society's 90th Annual Meeting in San Francisco.
Long-term hormone replacement therapy increases breast cancer risk
"Are you taking or did you take hormones? If yes, which hormone medication and for how long? When did you stop taking hormone replacement medication?" 3,464 breast cancer patients and 6,657 healthy women between the ages of 50 and 74 years participated in a large survey and elicited detailed information about hormone replacement medications they are taking or used to take for relief of menopausal symptoms.
Blood cholesterol levels predict risk of heart disease due to hormone therapy
A new analysis of a subgroup of participants in the Women's Health Initiative (WHI) hormone therapy clinical trials suggests that healthy, postmenopausal women whose blood cholesterol levels are normal or lower are not at increased, short-term risk for heart attack when taking hormone therapy.
Study finds it pays to be heart smart if considering hormone therapy
A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack.
More Hormone Therapy News Articles
 | From Belly Fat to Belly Flat: How Your Hormones Are Adding Inches to Your Waist and Subtracting Years from Your Life -- the Medically Proven Way to Reset Your Metabolism and Reshape Your Body by C.W. Randolph M.D., Genie James Discover the hidden culprit behind the 'middle-age spread'--and the simple plan that's helped hundreds of women over 30 break the fat cycle!It's an all-too-common problem once you hit thirty: Despite your best efforts, you just can't seem to lose the extra weight around your middle, and you look in the mirror wondering what month and year you lost your waistline. Medical research proves you're... |
 | The Fat Resistance Diet: Unlock the Secret of the Hormone Leptin to: Eliminate Cravings, Supercharge Your Metabolism, Fight Inflammation, Lose Weight & Reprogram Your Body to Stay Thin- by Leo Galland No more counting carbs, calories, or fat grams! This revolutionary diet plan works with your hormones to curb your appetite, boost your metabolism, and take the pounds off for good!Cutting-edge research shows that losing weight is not about carbs, calories, or even willpower—it’s about a hormone called leptin, and how it functions in your body. Leptin is your body’s natural... |
 | Energy Medicine for Women: Aligning Your Body's Energies to Boost Your Health and Vitality by Donna Eden, David Feinstein A women’s guide to using energy medicine to promote and maintain optimal physical and mental well-being. For more than three decades, Donna Eden has been teaching people to understand the body as an energy system, to recognize their aches and pains as signals of energy imbalance, and to reclaim their natural healing capabilities. In this long-awaited new book, Eden speaks directly to women,... |
 | What Your Doctor May Not Tell You About Menopause (TM): The Breakthrough Book on Natural Hormone Balance by John R. Lee, Virginia Hopkins The classic bestseller that has helped nearly a million women discover the answer to menopause is now revised and updated. Hot flashes, night sweats, weight gain, low sex drive, hair loss, fibroids, and osteoporosis-most women will experience these or other hormone- related problems at some point as they age. In clear, easy-to-understand language, an internationally recognized expert explains the... |
 | What Your Doctor May Not Tell You About(TM): Premenopause: Balance Your Hormones and Your Life from Thirty to Fifty (What Your Doctor May Not Tell You About...) by John R. Lee, Jesse Hanley, Virginia Hopkins |
 | Dr. John Lee's Hormone Balance Made Simple: The Essential How-to Guide to Symptoms, Dosage, Timing, and More by John R. Lee, Virginia Hopkins For nearly a decade, millions of women have turned to Dr. John Lees classic bestsellers for groundbreaking advice treating hormone imbalances from PMS to menopause and beyond. Now, this concise, comprehensive guide answers the questions posed by thousands of letters written to Dr. Lee by women seeking specific, simplified advice on what their symptoms mean, how to determine their hormone levels... |
 | The Miracle of Bio-Identical Hormones, 2nd edition by Michael E., M.D. Platt The 2nd edition of Dr. Platt's highly informative award-winning health book, The Miracle of Bio-Identical Hormones, How I Lost My Fatigue, Hot Flashes, ADHD, ADD, Fibromyalgia, PMS, Osteoporosis, Weight, Sexual Dysfunction, Anger, Migraines, provides many answers to common medical problems by explaining their underlying cause and how hormone balance brings you wellness. Outstanding praise for... |
 | New Glucose Revolution Guide to Living Well with PCOS by Dr. Jennie Brand-Miller, Nadir Farid, With * PCOS—Polycystic Ovarian Syndrome—is the most common hormonal disorder among women of child-bearing age, affecting approximately 6 to 10 percent of premenopausal women. No two women have the same symptoms, making it a difficult condition to diagnose. In addition, many women don't know they have it until they try to become pregnant. This breakthrough book contains the latest research... |
 | The Testosterone Syndrome: The Critical Factor for Energy, Health, and Sexuality--Reversing the Male Menopause by Eugene Shippen Testosterone therapy can improve the overall health and feeling of well-being of aging men, improving sex drive, mental functions, and energy levels and reducing the risk of cardiovascular disease.--Library... |
 | From Hormone Hell to Hormone Well: Discover Human-Identical Hormones as a Safe & Effective Treatment for PMS, Perimenopause, Menopause or Hysterectomy by C. W., Jr., M.D. Randolph, Genie James With devastating reports coming out about synthetic hormones, Dr. C.W. Randolph, Jr. was urged to write From Hormone Hell to Hormone Well . This book helps women around the world understand how their bodies can be treated effectively by using human-identical natural hormones - the safe way to a healthy life as the body changes. The book is written for women suffering from the symptoms... |
| © 2008 BrightSurf.com |